Clinical Trials Browser

Phase 1 × belantamab mafodotin × Plasma cell × Clear all

NCT05556798 2026-02-24

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

Phase 1 Active not recruiting

Multiple Myeloma

NCT05055063 2025-12-18

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Phase 1 Recruiting

Neoplasms, Plasma Cell

NCT04398680 2025-12-04

DREAMM 13

Phase 1 Withdrawn

Multiple Myeloma, Recurrence

NCT04091126 2025-11-28

DREAMM 9

Phase 1 Active not recruiting

Multiple Myeloma

NCT05065047 2025-11-12

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma

NCT03828292 2025-08-19

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Phase 1 Completed

15 enrolled 91 charts

Multiple Myeloma

NCT04398745 2025-05-23

DREAMM12

Phase 1 Active not recruiting

GenitourinaryPlasma cell

Kidney Failure, Chronic, Multiple Myeloma, Renal Insufficiency

NCT04892264 2025-05-18

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma

NCT04177823 2025-03-20

A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1 Completed

6 enrolled 48 charts

Multiple Myeloma

NCT02064387 2020-08-11

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

Phase 1 Completed

79 enrolled 59 charts

Multiple Myeloma